|
AU725609C
(en)
*
|
1995-08-18 |
2002-01-03 |
Morphosys Ag |
Protein/(poly)peptide libraries
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
AU1728800A
(en)
|
1998-11-18 |
2000-06-05 |
Genentech Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
|
ATE513563T1
(de)
*
|
2000-10-09 |
2011-07-15 |
Isis Innovation |
Therapeutische und toleranz-induzierende antikörper
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
US20040109855A1
(en)
*
|
2002-07-23 |
2004-06-10 |
Herman Waldmann |
Therapeutic antibodies with reduced side effect
|
|
AU2004226492A1
(en)
*
|
2003-03-31 |
2004-10-14 |
Kirin Beer Kabushiki Kaisha |
Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor
|
|
NZ550815A
(en)
*
|
2004-05-19 |
2009-04-30 |
Immunocore Ltd |
Method of improving T cell receptors
|
|
CA2601400A1
(en)
*
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
|
PE20070207A1
(es)
*
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
WO2008144484A1
(en)
*
|
2007-05-16 |
2008-11-27 |
Sinomab Bioscience Limited |
Functional humanization of complementarity determining regions (cdrs)
|
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
US20100189651A1
(en)
*
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
JP5861223B2
(ja)
*
|
2009-02-23 |
2016-02-16 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
プロタンパク質およびその使用方法
|
|
EP2998405B1
(en)
|
2009-05-13 |
2019-12-11 |
Genzyme Corporation |
Anti-human cd52 immunoglobulins
|
|
SG175407A1
(en)
|
2009-05-29 |
2011-11-28 |
Morphosys Ag |
A collection and methods for its use
|
|
RU2603080C2
(ru)
|
2010-11-19 |
2016-11-20 |
МорфоСис АГ |
Коллекция и способы ее применения
|
|
GB201109238D0
(en)
*
|
2011-06-01 |
2011-07-13 |
Antitope Ltd |
Antibodies
|
|
WO2013152011A1
(en)
*
|
2012-04-02 |
2013-10-10 |
Ab Biosciences, Inc. |
Novel human control antibodies and uses therefor
|
|
CN104540518A
(zh)
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
EP2983790A2
(en)
|
2013-04-09 |
2016-02-17 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
US9737623B2
(en)
|
2013-12-11 |
2017-08-22 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
US20160120158A1
(en)
*
|
2014-11-03 |
2016-05-05 |
The Johns Hopkins University |
Compositions and methods for the study and treatment of acute kidney injury
|
|
MX2017015618A
(es)
|
2015-06-03 |
2018-08-15 |
Boston Biomedical Inc |
Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
|
|
JP7106563B2
(ja)
|
2016-11-29 |
2022-07-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
ナフトフラン誘導体、その調製、および使用方法
|
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
US12465637B2
(en)
|
2019-04-30 |
2025-11-11 |
Institute For Cancer Research |
Compositions and methods for modulation of antibody activity
|